8282-Reduced: CDR132L in people with heart failure with reduced ejection fraction
Research type
Research Study
Full title
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
IRAS ID
1011246
Contact name
Clinical Transparency
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2024-515797-27
ISRCTN Number
N/A
Clinicaltrials.gov Identifier
Not available
Research summary
We are doing this study to see how the new medicine, called CDR132L, works on the structure and function of the heart in people living with heart failure. Heart failure is a condition in which the heart muscle is unable to pump enough blood to meet the body’s needs. If the heart has difficulties pumping effectively and not enough blood is pumped into the body with each heartbeat, the condition is known as heart failure with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF). Some people develop harmful changes in the heart muscle, and heart tissue can stiffen and get too thick (also known as left ventricular hypertrophy). No medicine exists that aims to improve these specific changes in the heart muscle.
REC name
Wales REC 2
REC reference
25/WA/0023
Date of REC Opinion
27 Mar 2025
REC opinion
Further Information Favourable Opinion